PER7 Antibody

How should researchers approach antibody selection for experimental design?

Antibody selection requires thorough consideration of target characteristics before beginning your search. According to recent scientific guidance, researchers should gather comprehensive information about their target molecule, including expression level, subcellular localization, structure, stability, and homology to related proteins . Additionally, consider whether your protein undergoes post-translational modifications or participates in signaling cascades, as this provides valuable insights into its biological context .

Before finalizing antibody selection, researchers should:

• Review target protein information in open-access resources (Uniprot, Human Protein Atlas)

• Assess published literature regarding target expression patterns

• Consider target protein structure and potential epitopes

• Evaluate whether post-translational modifications might affect antibody binding

• Determine appropriate species cross-reactivity requirements

What validation steps are essential before using antibodies in experiments?

Antibody validation is critical to ensure experimental success and reproducibility. Multiple search results emphasize the importance of pre-screening and validation steps:

• Pre-immune screening - Select optimal animals before starting antibody production by testing serum samples for cross-reactivity with your target or assay components

• Pre-immune test bleed - Acquire negative controls from the same animals that will generate antibodies

• Small test bleed - Monitor antibody titer evolution after one month during longer programs

• Species-specificity confirmation - Validate specificity using appropriate positive and negative controls

For example, with the anti-human P2X7 antibody (clone L4), specificity was confirmed using flow cytometric assays of human RPMI 8266 and murine J774 cells to verify that the antibody bound and impaired human P2X7 but not murine P2X7 .

What controls should be included when using antibodies against clock proteins?

When working with antibodies targeting circadian clock proteins such as PER1, PER2, BMAL1, and CLOCK, proper controls are essential for accurate interpretation. Research indicates that antibody validation should include:

• Temporal controls - Examining mice and hamsters at peak and trough times of clock protein expression in the suprachiasmatic nucleus (SCN)

• Genetic controls - Testing antibodies on mice with targeted disruption of the relevant genes

• Species-appropriate secondary antibodies - Particularly important as some products are derived from guinea pig rather than rabbit or mouse

A comprehensive table of available antibodies for circadian rhythm research with their specific applications shows:

*The use is reported in research articles

How can antibodies be effectively used to study the P2X7 receptor in immune-related research?

The P2X7 receptor, an extracellular adenosine 5'-triphosphate-gated cation channel expressed on immune cells, plays significant roles in inflammatory responses. Advanced applications of anti-P2X7 antibodies include:

• Flow cytometric analysis for expression studies - Anti-human P2X7 monoclonal antibody (clone L4) has been validated for analyzing P2X7 expression on primary leukocytes, keratinocytes, osteoblasts, neuronal cells, and various cell lines

• Gene variant characterization - The antibody has been used to characterize polymorphic variants and isoforms of the P2RX7 gene and P2X7 site-directed mutations

• Co-association studies - Identification of molecules co-associated with P2X7 in the plasma membrane

• Mechanistic studies of therapeutic interventions - In vivo administration of anti-hP2X7 mAb (100 μg i.p. per mouse on days 0, 2, 4, 6, and 8) was shown to increase human regulatory T cells and human natural killer cells at Day 21 in disease models

For researchers studying graft-versus-host disease (GVHD), recent findings show that blockade of human (donor) P2X7 reduces GVHD development in humanized mice, providing direct evidence of donor P2X7's role in GVHD .

What methodological approaches are recommended for using antibodies in kinetically controlled proteomics for undruggable targets?

For difficult-to-drug targets like ion channels and G protein-coupled receptors, innovative antibody development strategies have emerged. A novel approach involves:

• Using kinetically controlled proteases as structural dynamics-sensitive druggability probes in native-state proteins

• Employing low–Reynolds number flows to make limited protease incisions

• Identifying antibody binding sites (epitopes) that can be translated into short-sequence antigens for antibody production

• Obtaining molecular-level information of the epitope-paratope region

This methodology comprises distinct steps:

• Using "antibody-like" proteases as freely diffusing molecular probes

• Controlling protease activity to identify epitopes on native, disease-relevant target structures

• Creating antigen libraries with sequence alterations (elongations, truncations, amino acid exchanges)

• Developing high-affinity binding antibodies through systematic epitope interrogation

For example, in TRPV1 research, a digestion protocol with proteinase K (5 μg/ml) for 5 minutes identified 19 potential interaction clusters (PICs), with two located in the prepore EC loop preceding the pore region being particularly promising for therapeutic antibody development .

How should researchers design experiments to accurately detect circadian protein expression patterns?

Detecting circadian protein expression patterns requires specialized experimental design. Recent advances in circadian rhythm research suggest:

• Time-course sampling - Analyzing proteins at multiple time points throughout the circadian cycle to capture peak and trough expression levels

• Multiple detection methods - Combining immunohistochemistry (IHC) with western blotting (WB) and chromatin immunoprecipitation (ChIP) for comprehensive analysis

• Post-translational modification analysis - Investigating phosphorylation and ubiquitination, particularly for PER and CRY proteins

Researchers should be aware that post-translational modifications are crucial for understanding circadian rhythm mechanisms. For instance, phosphorylation and ubiquitination of PER and ubiquitination of CRY proteins are well-established regulatory mechanisms . Using antibodies that can detect these modifications provides greater insight into the molecular mechanisms of circadian rhythm.

How should researchers deal with contradictory data when validating antibody specificity?

When facing contradictory data during antibody validation, a systematic approach is recommended:

• Examine the data thoroughly to identify discrepancies

• Evaluate initial assumptions and research design

• Consider alternative explanations for contradictory results

• Modify data collection processes if necessary

• Refine variables and implement additional controls

When evaluating alternative explanations, researchers should:

• Review research design and methodology

• Examine data collection processes

• Analyze variables and controls

Always remain open to challenging initial assumptions and be willing to adjust approaches as necessary.

What strategies can address regional variations in antibody-mediated detection?

Geographic variations in antibody detection sensitivity can significantly impact research outcomes. A compelling example comes from Chagas disease research, where antibody titers among seropositive individuals were significantly lower in Arequipa, Peru, compared with Santa Cruz, Bolivia .

To address such regional variations:

• Implement parallel T-cell response testing - In the Chagas study, IFNγ-ELISPOT assays were used to measure parasite-specific T-cell responses to complement antibody testing

• Calculate region-specific cutoff values - Establish distinct thresholds for different geographical areas

• Employ multiple detection methods - Combine antibody testing with cellular response assays

• Use standardized stimulation protocols - For example, stimulating 4×10^5 PBMCs with 25 μg/mL antigen lysate for 16–20 hours

When testing responses to different strains, researchers found that over 80% of ELISPOT responders reacted to three or more parasite strains, with similar frequencies of IFNγ-producing cells observed across responsive samples .

How can researchers optimize antibody-based detection in challenging sample types?

Optimizing antibody-based detection in difficult samples requires careful consideration of several factors:

• Sample preparation techniques - Ensure proper handling to maintain epitope integrity

• Buffer optimization - Adjust composition to minimize background and maximize signal

• Blocking reagent selection - Choose appropriate blockers to reduce non-specific binding

• Incubation conditions - Optimize temperature, time, and agitation parameters

• Signal amplification strategies - Implement when working with low-abundance targets

For serum samples, evidence suggests proper collection techniques significantly impact results. For instance, serum obtained using the Vacutainer®-system provides clearer samples with minimal hemoglobin contamination (<1 g/l) compared to other methods that can produce red serum with higher hemoglobin concentrations, potentially affecting immune staining experiments due to increased fluorescent or HRP-reactive background .

How are antibodies being integrated into research on disease mechanisms and therapeutic development?

Antibodies are increasingly critical in understanding disease mechanisms and developing targeted therapeutics. Recent research demonstrates:

• Anti-P2X7 antibodies in GVHD - Blockade of human P2X7 with monoclonal antibodies reduced clinical and histological GVHD in the liver and lung compared to control treatment, while increasing human regulatory T cells, human natural killer cells, and human natural killer T cell proportions

• Circadian clock proteins in cancer immunotherapy - The circadian clock component RORA forms a corepressor complex to inhibit PD-L1 expression and activate antitumor T-cell responses. The combination of a RORA agonist with an anti-CTLA4 antibody synergistically increased T-cell antitumor immunity in vivo, suggesting RORA as a potential target and predictive biomarker to improve immunotherapy response in melanoma patients

These applications represent frontiers where antibody-based research is unveiling new therapeutic strategies and mechanistic insights.

What advances in computational approaches are improving antibody design and prediction?

Computational methods are transforming antibody research, particularly in predicting and addressing stability challenges:

• Machine learning for deamidation prediction - Advanced models are now combining supervised machine learning with comprehensive datasets to predict deamidation propensities throughout entire antibody sequences

• Structure-based models - Unlike conventional sequence-based models, structure-based approaches incorporate secondary structure, tertiary structure, solvent accessible surface area (SASA), backbone, and side-chain dihedral angles to improve prediction accuracy

• Integrated approaches - Combining experimental high-throughput automated peptide mapping with computational modeling has created comprehensive antibody deamidation-specific datasets (n = 2285) spanning various antibody modalities

These computational advances are critical for predicting and addressing chemical degradations like deamidation, where asparagine (N) and glutamine (Q) residues undergo modifications that can negatively impact efficacy, stability, and safety of diverse antibody classes .

How will antibody research evolve to address currently undruggable targets?

Technological innovations are expanding the frontiers of antibody research to previously undruggable targets:

• Dynamic structural targeting - Next-generation approaches recognize that proteins expose different accessible regions dynamically, using proteases as molecular probes that adapt to real-time structural motion

• Epitope-paratope optimization - Advanced platforms produce antigens for potential epitopes identified on native-state, disease-relevant proteins in motion, with detailed knowledge of both the epitope and paratope sequence to yield required disease-modifying functionality

• Stimulus-selective pharmacological profiles - For targets like ion channels, novel approaches identify potential binding sites in functional domains like the prepore EC loop, enabling development of antibodies with different pharmacological profiles than classical small-molecule antagonists

These innovations represent a significant shift from traditional antibody development approaches, potentially unlocking therapeutic opportunities for previously inaccessible targets and enabling more precise modulation of biological processes.

What protocols are recommended for flow cytometric analysis using anti-P2X7 antibodies?

For researchers conducting flow cytometric analysis with anti-P2X7 antibodies, standardized protocols have been established:

• Cell preparation - Maintain consistent cell density and viability across samples

• Antibody dilution optimization - Each laboratory should determine optimal dilutions for their specific applications

• Staining protocol - For human peripheral blood lymphocytes, dual staining with anti-human CD4 APC-conjugated monoclonal antibody and anti-human P2X7 PE-conjugated monoclonal antibody is recommended

• Appropriate controls - Include isotype controls such as Mouse IgG2A-Phycoerythrin

For specificity validation, researchers can use transfected cell lines, comparing reactivity between target-expressing cells (e.g., HEK293 human embryonic kidney cells transfected with human P2X7) and irrelevant transfectants . Antibody binding can be monitored using secondary antibodies such as Phycoerythrin-conjugated Anti-Mouse IgG .

What considerations are important when designing experiments to analyze protein-protein interactions in circadian rhythm research?

When investigating protein-protein interactions in circadian clock systems:

• Temporal coordination - Design experiments to capture interactions at specific circadian time points

• Complex formation analysis - The BMAL1-CLOCK heterodimer binds to E-box elements in per1/2 and cry1/2 genes, while PER and CRY proteins form a complex that negatively regulates BMAL1-CLOCK function

• Post-translational modification assessment - Pay particular attention to phosphorylation and ubiquitination patterns of clock proteins

• Application-specific antibody selection - Choose antibodies validated for specific applications such as chromatin immunoprecipitation to study DNA-protein interactions

The core feedback loop of circadian rhythm involves BMAL1 and CLOCK forming a heterodimer that binds to regulatory regions in per1/2 and cry1/2 genes. The resulting PER and CRY proteins then form complexes that migrate to the nucleus and negatively regulate BMAL1-CLOCK function . Selecting antibodies validated for these specific interaction studies is crucial for successful experimental outcomes.

How should researchers approach antibody selection for complex experimental designs involving multiple detection methods?

For complex experimental designs requiring multiple detection methods:

• Application compatibility assessment - Prioritize antibodies validated across required applications (WB, IP, IHC, ChIP)

• Epitope location consideration - Select antibodies targeting epitopes that remain accessible in different experimental conditions

• Cross-validation strategy - Employ multiple antibodies targeting different epitopes of the same protein

• Buffer compatibility planning - Ensure antibodies function in buffers suitable for all planned applications

When selecting antibodies for complex studies, researchers should examine detailed validation data for each application. For example, antibodies against circadian rhythm proteins have different application profiles:

• Anti-PER1 and PER2 antibodies are validated for Western blot (WB), immunoprecipitation (IP), and immunohistochemistry (IHC)

• Anti-BMAL1 and CLOCK antibodies can be used for WB, IHC, and ChromatIn Immunoprecipitation (ChIP)

• Application compatibility should be verified through published validation data or preliminary testing

This comprehensive approach ensures that selected antibodies will perform consistently across all experimental conditions, enhancing reproducibility and reliability of complex research designs.